Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner, MD, Joan H Schiller, MD, Arnold Herskovic, MD, Ritsuko Komaki, MD, Randolph S Marks, MD, Michael C Perry, MD, Robert B Livingston, MD, David H Johnson, MD The Journal of Thoracic and Cardiovascular Surgery Volume 128, Issue 1, Pages 130-137 (July 2004) DOI: 10.1016/j.jtcvs.2003.11.061
Figure 1 Median survival was 65.4 months (95% CI, 45-88.8 months) for patients with N1 disease and 30.6 months (95% CI, 22.3-38.6 months) for all patients with N2 disease; 5-year survivals were 52% and 32%, respectively. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)
Figure 2 Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 49.4 months (95% CI, 25.4-89 months) for patients with left upper lobe tumors and N1 disease; 5-year survival was 42% in both groups. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)
Figure 3 Median survival was 20 months (95% CI, 14.3-53.4 months) for patients with multi-level N2 disease and 35.3 months (95% CI, 26.9-39.9 months) for patients with single-level N2 disease. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)
Figure 4 Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 18.2 months (95% CI, 7.6 months–not reached) for patients with multiple-level N2 disease. The difference approximated statistical significance. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)
Figure 5 Median survival was 58.8 months (95% CI, 35.5-106.7 months) for patients with solitary N2 skip metastases compared with 25.6 months (95% CI, 16.2-35.9 months) for patients with concomitant N1 and N2 disease; 5-year survivals were 50% and 18%, respectively. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)